.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA32_Apremilast.Apremilast .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA32_Apremilast.Apremilast| name: | Apremilast |
| ATC code: | L04AA32 | route: | oral |
| n-compartments | 2 |
Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), used for the treatment of adults with moderate to severe plaque psoriasis and active psoriatic arthritis. It is approved and marketed for these indications.
Pharmacokinetic parameters from healthy adult volunteers after oral administration in a fasted state.
Huh, KY, et al., & Lee, H (2021). Pharmacokinetics and tolerability of apremilast in healthy Korean adult men. Clinical and translational science 14(4) 1505–1511. DOI:10.1111/cts.13013 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33932093
Bai, W, et al., & Dong, Z (2024). Pharmacokinetics and Bioequivalence of Apremilast Tablets in Chinese Healthy Subjects Under Fasting and Postprandial States. Drug design, development and therapy 18 2273–2285. DOI:10.2147/DDDT.S461771 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38895175
Deeks, ED (2015). Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs 75(12) 1393–1403. DOI:10.1007/s40265-015-0439-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26220911